Research summary ·
Comparative Outcomes of Propranolol and Corticosteroids in Infantile Haemangiomas: A Systematic Review and Meta-Analysis.
Written based on 1 research study on PubMed, searched on 7 Nov 2026.
What was studied
This was a pooled review of propranolol versus corticosteroids for infantile haemangiomas (IH). IH are benign vascular tumours that start in infancy. Propranolol is now first-line. Steroids are second-line or add-on. The team compared oral propranolol with oral and intralesional corticosteroids. They searched several databases on April 15, 2025.
What they found
1841 patients were included. Propranolol worked significantly better overall than corticosteroids, with an odds ratio of 4.96. Against oral corticosteroids, the odds ratio was 6.56. It showed no difference against intralesional corticosteroids. Adverse event odds were lower with propranolol, at 0.27. Ulceration odds were lower too, at 0.18.
What it means for patients
The authors said propranolol had greater overall effect than corticosteroids. It also had fewer adverse events. They said the gain was seen against oral corticosteroids but not intralesional ones. They said intralesional steroids may stay appropriate for selected patients. They said route and lesion traits matter when choosing.
Why it is not certain yet
Intralesional steroids showed no difference from propranolol. Ranges around some odds ratios were wide. The abstract names route and lesion traits as factors to weigh. A pooled analysis depends on how alike the studies are.
Source
Comparative Outcomes of Propranolol and Corticosteroids in Infantile Haemangiomas: A Systematic Review and Meta-Analysis.
PubMed · PMID 42980098We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Childhood cancers publications